Drugs Containing Excipient (Inactive Ingredient) CALCIUM HYDROXYAPATITE

Branded drugs containing CALCIUM HYDROXYAPATITE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	PREMARIN	estrogens, conjugated	50090-0167	CALCIUM HYDROXYAPATITE

Generic drugs containing CALCIUM HYDROXYAPATITE excipient

Company	Ingredient	NDC	Excipient
A-S Medication Solutions	estrogens, conjugated	50090-0167	CALCIUM HYDROXYAPATITE

Calcium Hydroxyapatite Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: October 6, 2026

Calcium hydroxyapatite is a niche pharmaceutical and biomaterials material with stronger commercial prospects in injectable drug delivery, dental products, bone substitutes, and medical devices than in conventional oral excipient applications. Its chemical formula is Ca10(PO4)6(OH)2. The market has no single standardized public revenue series because suppliers report calcium hydroxyapatite within broader categories such as bioceramics, bone-graft materials, calcium phosphates, dental materials, or drug-delivery systems.

The commercial outlook is positive but segmented. Growth is likely to be fastest in high-purity, controlled-particle-size grades used in drug delivery and regenerative medicine. Commodity powder grades face price competition, qualification barriers, and substitution by calcium phosphate, silica, magnesium silicate, microcrystalline cellulose, and polymeric carriers.

What is calcium hydroxyapatite used for in pharmaceutical products?

Calcium hydroxyapatite is used primarily as a mineral carrier, adsorbent, drug-delivery matrix, and bioactive calcium-phosphate component.

Application	Commercial role	Market attractiveness
Oral solid dosage forms	Adsorbent, mineral source, carrier, or formulation aid	Low to moderate
Injectable drug delivery	Carrier for local or sustained release	High
Bone and dental products	Bone substitute, scaffold, coating, or filler	High
Vaccine and biologic formulation research	Adsorption and controlled-release matrix	Moderate
Topical and cosmetic products	Mineral filler or active component	Moderate
Medical devices	Bioactive coating and resorbable ceramic	High
Cell culture and tissue engineering	Scaffold and surface material	Moderate to high

Hydroxyapatite has a composition similar to the inorganic mineral phase of bone. Its surface can adsorb proteins, peptides, nucleic acids, and certain small molecules. That property supports local drug delivery and tissue-regeneration applications, but it also creates formulation risks. Adsorption can reduce free drug concentration, complicate dose uniformity, and make release profiles sensitive to particle size, crystallinity, porosity, pH, and surface chemistry.

How large is the calcium hydroxyapatite pharmaceutical excipient market?

A reliable standalone global market size is not publicly established. Public market reports generally combine calcium hydroxyapatite with broader segments, including:

• synthetic bone grafts;
• bioceramics;
• calcium phosphate ceramics;
• dental biomaterials;
• drug-delivery materials;
• injectable dermal fillers;
• orthopedic coatings.

The pharmaceutical-excipient component is materially smaller than the medical-device and dental segments. Revenue is concentrated in specialty grades rather than bulk pharmaceutical excipient volumes.

The relevant economic distinction is between commodity and functional-grade material:

Grade	Typical specifications	Pricing and margin profile
Commodity powder	Broad particle-size distribution and standard purity	Low price, limited differentiation
Pharmaceutical grade	Controlled impurities, documentation, validated manufacturing	Higher price and qualification barriers
Injectable grade	Sterility, endotoxin controls, tight particle-size limits	High price and high compliance cost
Nano-hydroxyapatite	Controlled morphology, surface area, and crystallinity	Premium pricing, technical qualification
Porous or drug-loaded grade	Engineered pore structure and release performance	Highest technical value

Specialty grades can command substantially higher prices than commodity calcium phosphate powders, but volumes are smaller. The economic model resembles a specialty-materials business rather than a high-volume tablet excipient business.

What factors are driving demand for calcium hydroxyapatite?

The main demand drivers are local drug delivery, regenerative medicine, dental repair, and medical-device coating applications.

Local and sustained drug delivery

Hydroxyapatite can act as a depot for antibiotics, anticancer agents, growth factors, peptides, and other active substances. Local delivery can reduce systemic exposure and concentrate treatment at bone or dental sites.

Commercial adoption depends on release reproducibility. A supplier must control:

• crystal phase;
• calcium-to-phosphorus ratio;
• particle size;
• porosity;
• specific surface area;
• residual solvents and reagents;
• microbial burden and endotoxin;
• heavy metals;
• sterilization compatibility.

These parameters create a technical barrier that is more important than the basic composition patent position.

Bone and dental applications

Bone substitutes and dental materials remain the largest commercial opportunity for hydroxyapatite-related products. The material can be formulated as granules, blocks, coatings, pastes, composites, or injectable cements.

These products are usually regulated as medical devices rather than pharmaceutical excipients. Their sales therefore do not directly reflect pharmaceutical-excipient demand, although they support manufacturing scale, supplier qualification, and process know-how.

Nano-hydroxyapatite

Nano-hydroxyapatite is marketed for dental remineralization, tissue engineering, and advanced drug delivery. Its higher surface area can improve loading capacity but can also increase aggregation, batch variability, toxicology requirements, and analytical complexity.

Nano-grade products have better margin potential than standard powders. They also face a longer development cycle because the sponsor must characterize particle behavior, biodistribution, degradation, and impurity profiles.

What is the FDA regulatory status of calcium hydroxyapatite?

Calcium hydroxyapatite does not have a single FDA status that applies across all uses. The regulatory pathway depends on its function, route of administration, product claims, and presentation.

Pharmaceutical excipient status

FDA regulation of inactive ingredients is product- and route-specific. Inclusion in the FDA Inactive Ingredient Database, where applicable, does not create an independent approval for every use or concentration. Sponsors must establish suitability for the intended dosage form, route, concentration, manufacturing process, and patient population.

The FDA evaluates excipients through the finished drug application, including an NDA, ANDA, or other applicable pathway. A calcium hydroxyapatite grade used in a medical device is not automatically acceptable as an excipient in an injectable drug.

Medical-device status

Calcium hydroxylapatite is used in cleared or approved medical devices, including bone substitutes, dental products, and dermal fillers. Radiesse, a calcium hydroxylapatite microsphere product, received FDA approval through the premarket approval pathway for specified aesthetic and reconstructive indications. That approval does not establish calcium hydroxyapatite as a generally approved pharmaceutical excipient.[1]

European regulatory position

European qualification depends on the product category. Pharmaceutical excipient use is assessed through the marketing authorization and applicable European Pharmacopoeia, quality, and safety requirements. Medical-device products are assessed under the EU Medical Device Regulation when they fall within its scope.[2]

What patents protect calcium hydroxyapatite products?

The basic composition of hydroxyapatite is old and cannot support a new broad composition patent. Commercial patent value generally lies in product engineering and application claims.

Patent subject	Typical claim focus	Commercial relevance
Manufacturing process	Wet precipitation, sintering, hydrothermal synthesis, spray drying	Moderate
Particle morphology	Rod, spherical, porous, whisker, or nanoscale particles	High
Surface modification	Polymer, peptide, silane, lipid, or ligand coating	High
Drug loading	Adsorption, encapsulation, covalent attachment, or depot release	High
Composite materials	Hydroxyapatite with collagen, polymers, or ceramics	High
Medical use	Bone repair, dental repair, local antibiotic or anticancer delivery	High
Sterilization and packaging	Stability and terminal sterilization methods	Moderate

The strongest enforceable positions are usually narrow patents covering a defined particle architecture, a drug-loaded formulation, a manufacturing parameter set, or a particular medical use. Broad claims to hydroxyapatite itself are vulnerable to prior-art challenges.

What is the patent expiration profile?

Foundational hydroxyapatite composition and early biomaterials patents are generally expired or close to expiration because the material has been studied for decades. Later patents directed to nano-hydroxyapatite, drug-loaded particles, surface-functionalized materials, and combination scaffolds may remain active into the late 2020s and 2030s, depending on priority dates and patent-term adjustments.

Patent analysis must be performed by product and jurisdiction. A supplier’s freedom to operate may depend more on process and application patents than on the chemical identity of the excipient.

Does calcium hydroxyapatite have Orange Book listings or Paragraph IV challenges?

Calcium hydroxyapatite itself does not have an Orange Book listing as an active pharmaceutical ingredient. The Orange Book lists approved drug products, patents, and exclusivity associated with approved finished drugs, not a standalone excipient market.

Paragraph IV litigation is therefore not normally directed at calcium hydroxyapatite as an excipient. A generic drug containing the material could challenge patents listed for the finished reference product, but those patents would generally concern the active ingredient, dosage form, formulation, or method of use.

For sponsors using hydroxyapatite in an ANDA, the relevant risks include:

• formulation patents covering the reference product;
• method-of-use patents;
• device-drug combination claims;
• manufacturing-process patents;
• supplier restrictions or proprietary material specifications.

How strong is the patent estate for calcium hydroxyapatite?

The overall patent estate is moderate in technical depth but weak at the level of basic composition.

Stronger areas

• nano-hydroxyapatite with defined morphology;
• drug-loaded injectable depots;
• surface-functionalized particles;
• hydroxyapatite-polymer composites;
• dental remineralization formulations;
• antibiotic and anticancer local-delivery systems;
• 3D-printed or porous scaffolds.

Weaker areas

• generic calcium hydroxyapatite powder;
• conventional sintered hydroxyapatite;
• broad claims to calcium-phosphate bone substitutes;
• standard adsorbent uses without defined performance parameters.

Patent strength depends on reproducibility. Claims that define measurable particle characteristics, release kinetics, purity limits, and clinical performance are more defensible than claims based only on the presence of hydroxyapatite.

Which companies supply or commercialize hydroxyapatite?

The supply chain includes specialty bioceramic manufacturers, dental-material suppliers, medical-device companies, research-grade chemical suppliers, and contract manufacturers. Commercial activity is fragmented, and many suppliers do not report hydroxyapatite revenue separately.

Known market participants and adjacent suppliers include:

• Stryker, through orthopedic and biomaterial products;
• Zimmer Biomet, through bone-repair and orthopedic materials;
• Berkeley Advanced Biomaterials, associated with calcium-phosphate biomaterials;
• CAM Bioceramics;
• Fluidinova;
• Himed;
• Plasma Biotal;
• Merck and Thermo Fisher Scientific, primarily through research and specialty chemical channels;
• dental-material and bone-graft manufacturers using hydroxyapatite as an intermediate or finished-product component.

The list does not imply that each company sells pharmaceutical-excipient-grade material or competes in every geographic market.

What licensing deals and commercial partnerships affect the market?

Public licensing activity is limited because hydroxyapatite is often sold through supply, contract manufacturing, or component agreements rather than high-value drug licenses.

The main transaction structures are:

1. material-supply agreements;
2. co-development of drug-loaded particles;
3. contract manufacturing of sterile or injectable grades;
4. licensing of scaffold or delivery technologies;
5. OEM supply for dental and orthopedic devices.

Royalty-bearing licenses are more likely in products that combine hydroxyapatite with a proprietary active ingredient, polymer, biologic, implant, or delivery platform. The excipient itself is usually not the principal economic asset in the transaction.

What manufacturing and intellectual-property barriers exist?

Manufacturing scale is available, but pharmaceutical-grade consistency is difficult. Key barriers include:

• control of crystallinity and phase purity;
• reproducible calcium-to-phosphorus stoichiometry;
• removal of residual solvents and reagents;
• low endotoxin and bioburden;
• particle-size and morphology control;
• sterilization without changing surface properties;
• stable dispersion in injectable vehicles;
• validated analytical methods;
• supply-chain traceability for critical raw materials.

The highest barriers apply to sterile injectable material and drug-loaded systems. A sponsor may qualify multiple suppliers for commodity powder but rely on one supplier for a validated nano-grade or surface-modified material.

What is the financial trajectory for calcium hydroxyapatite?

The financial trajectory is likely to be bifurcated.

Segment	Expected trajectory	Financial profile
Bulk powder	Stable to modest growth	Low margins and strong price competition
Pharmaceutical-grade excipient	Moderate growth	Better margins after qualification
Injectable and sterile grades	Above-market growth	High validation and compliance costs
Drug-delivery platforms	High potential, uneven timing	Dependent on clinical and regulatory success
Dental products	Durable growth	Established demand and moderate differentiation
Orthopedic biomaterials	Durable but competitive	Procedure volumes and reimbursement dependent
Research-grade material	Stable niche demand	Small market, higher unit pricing

Revenue exposure is difficult to isolate because public companies typically aggregate hydroxyapatite within broader biomaterials, orthopedic, dental, or medical-device segments. Financial performance will depend more on downstream product adoption than on raw-material volume.

The most attractive commercial position is an integrated supplier that sells validated material together with formulation support, analytical data, sterilization capability, and regulatory documentation. A commodity producer is more exposed to price pressure and customer switching.

How does calcium hydroxyapatite compare with competing excipients?

Material	Primary advantage	Main limitation
Calcium hydroxyapatite	Bioactivity and mineral affinity	Low solubility and complex release behavior
Dibasic calcium phosphate	Established tablet excipient	Limited suitability for advanced delivery
Tricalcium phosphate	Calcium-phosphate functionality	Variable dissolution and processing behavior
Silica	Strong adsorption and flow improvement	Limited bioactivity and inhalation concerns
Microcrystalline cellulose	Established oral-excipient platform	Not suitable for mineralized tissue applications
PLGA	Proven controlled-release polymer	Acidic degradation products and higher cost
Collagen	Biocompatibility and tissue affinity	Animal-source, stability, and variability concerns

Hydroxyapatite competes successfully where bioactivity, mineral composition, or local tissue targeting matters. It is less competitive in standard tablets where low cost, compressibility, flow, and global regulatory familiarity dominate.

What generic launch and biosimilar risks exist?

Generic risk is indirect. A generic drug sponsor can replace or reproduce a hydroxyapatite-containing formulation if the material is nonproprietary and the finished product does not depend on a protected particle structure or manufacturing process.

Risk is higher when:

• the reference product uses a distinctive drug-loaded particle;
• the hydroxyapatite has a patented morphology;
• release depends on proprietary surface chemistry;
• the product is a drug-device combination;
• the supplier has a locked specification;
• the formulation has device or method-of-use patents.

Biosimilar risk is generally not relevant to calcium hydroxyapatite itself. It becomes relevant only when hydroxyapatite is used as a delivery component for a biologic or in a combination product involving a biologic active ingredient.

Key Takeaways

• Calcium hydroxyapatite is a specialty material, not a large conventional excipient category.
• Its strongest commercial opportunities are injectable delivery, bone repair, dental products, and medical devices.
• Public revenue data do not isolate pharmaceutical-excipient sales from broader calcium-phosphate and bioceramic markets.
• Basic composition patents offer limited protection because hydroxyapatite is an established material.
• Commercial patent value is concentrated in morphology, surface treatment, drug loading, composites, and manufacturing processes.
• Orange Book listings and Paragraph IV challenges generally apply to finished drug products, not calcium hydroxyapatite itself.
• Sterile, nano, porous, and functionalized grades have higher pricing potential but face heavier qualification and regulatory requirements.
• The strongest business model combines material supply with formulation development, analytical support, and validated manufacturing.

FAQs

Is calcium hydroxyapatite an FDA-approved pharmaceutical excipient?

Its acceptability depends on the specific product, route, concentration, and regulatory filing. FDA approval of a product containing calcium hydroxyapatite does not create universal approval for all pharmaceutical uses.

Is hydroxyapatite the same as calcium phosphate?

No. Hydroxyapatite is a specific calcium-phosphate mineral with the formula Ca10(PO4)6(OH)2. Calcium phosphate is a broader category that includes tricalcium phosphate, dibasic calcium phosphate, and other compounds.

Can calcium hydroxyapatite be used in injectable drugs?

It can be used in injectable delivery systems and combination products, but injectable use requires control of sterility, endotoxin, particle size, impurities, injectability, and tissue compatibility.

Are hydroxyapatite excipient patents blocking generic drug entry?

Usually not by themselves. Generic entry risk depends on patents covering the finished product, formulation, delivery system, method of use, or manufacturing process.

Which hydroxyapatite grade has the highest commercial value?

Sterile nano-hydroxyapatite, porous drug-loaded particles, and surface-functionalized grades generally have higher commercial value than standard bulk powder because they require specialized manufacturing and technical qualification.

References

1. U.S. Food and Drug Administration. (2006). Radiesse injectable implant: Premarket approval application P060023. https://www.accessdata.fda.gov/cdrh_docs/pdf6/P060023.html

2. European Parliament and Council of the European Union. (2017). Regulation (EU) 2017/745 on medical devices. https://eur-lex.europa.eu/eli/reg/2017/745/oj

3. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

5. U.S. Pharmacopeial Convention. (n.d.). USP-NF and pharmaceutical excipients resources. https://www.usp.org

6. Dorozhkin, S. V. (2010). Bioceramics of calcium orthophosphates. Biomaterials, 31(7), 1465-1485. https://doi.org/10.1016/j.biomaterials.2009.12.007